The global death toll of AIDS has reached 25 million, while approximately 40 million people are now living with HIV/AIDS. Despite of the adoption of the Highly Active Anti-Retroviral Therapy (HAART), significant challenges remain for effective HIV treatment, such as:
• Overcome viral drug resistance: HIV constantly mutates to evade drug inhibition
• Achieve better efficacy and safety: many treatment regimens have significant toxicity
• Improve treatment convenience: less frequent dosing to improve patient compliance and quality of life

Fusion inhibitors, a new generation of anti-AIDS drugs, target the critical fusion steps during HIV infection cycle; thereby prevent HIV from entering into host cells. Since fusion inhibitors target highly conserved regions involved in HIV fusion, they tend to be less likely to induce drug resistance than traditional anti-HIV drugs. Furthermore, fusion inhibitors targeting the viral proteins have less toxicity concern since they do not specifically bind to human endogenous proteins.

FusoGen's fusion inhibitor, Sifuvirtide [pronounced si-fu-ver-taid], was rationally designed based on the 3-dimentional structure of HIV gp41 protein. Compared to the marketed drug, Sifuvirtide offers major advantage in drug potency, safety, cost, and convenience.